

## Technology Advisory Committee A Interests Register

**Topic: Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]**

**Publication Date: 29/06/2022**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Samreen Ahmed	Clinical expert	Direct financial	Professor Ahmed has received consultancy, lecture fees and travel grants from Merck Sharp & Dohme	N/A	No date on nomination form and not referenced in the naming of the doc	N/A	It was agreed her declaration would not prevent Professor Ahmed from providing expert advice to the committee.
Holly Heath	Patient expert	Indirect financial	Breast Cancer Now has received funding from comparator companies Roche and Pfizer, she noted that they have not received any funding in the last 12 months Merck Sharp & Dohme.	N/A	10.11.2020	N/A	It was agreed that her declarations would not prevent Holly from providing expert advice to the committee.